Thermo Fisher introduces liver toxicity test
Assesses liver toxicity risk earlier in the development process
Thermo Fisher Scientific’s ToxInsight DILI Assay Cartridge is a new tool for assessing the liver toxicity risk of chemical compounds.
The US firm says it will help pharmaceutical companies improve their productivity by assessing liver toxicity early in the drug development process, specifically reducing the risk of drug-induced liver injury (DILI), which is a primary reason for post-market drug withdrawal.
Used with the ToxInsight IVT image cytometry platform, the ToxInsight DILI Assay Cartridge identifies drug induced hepatotoxicity by simultaneous detection of multiplexed toxicity biomarkers in single cells. It includes all the reagents, assay protocols, analysis and data reporting capabilities to profile compounds for hepatotoxicity with high sensitivity and specificity. The cartridge has been validated with a known hepatotoxic compound on hepatic cell-lines, including rat and human primary hepatocytes.
Thermo Fisher says the key to the predictive power of the DILI Assay Cartridge is powerful analytical and visualisation software that makes sense of the multi-parameter data from the cartridge. The software supports analysis and toxicity prediction of compounds with broad mechanisms of action because it monitors multiple, independent toxicity indicators. Intuitive visualisation tools provide users with graphs of individual responses for selected compounds and of predicted toxicity, so they can swiftly report a compound’s risk of liver injury in minutes.